MEDIOLANUM CARDIO RESEARCH SRL

Their core work

Mediolanum Cardio Research is a Milan-based private clinical research organization that bridges cardiovascular and neurodegenerative disease research. Their work spans computational modelling of cardiovascular devices (in-silico trials for drug-eluting bioresorbable vascular scaffolds) and clinical research into dementia care and palliative approaches for Parkinson's disease. They contribute clinical expertise and health economics analysis to EU research consortia, with a particular focus on evaluating care interventions and treatment cost-effectiveness.

What they specialise in

How they've shifted over time

Mediolanum Cardio Research started in 2017 with cardiovascular computational work (InSilc), consistent with their company name and founding mission. By 2018-2019, they pivoted decisively toward neurodegenerative diseases — first dementia behavioural management (RECAGE), then Parkinson's palliative care (PD_Pal). This shift suggests a deliberate expansion from device-oriented cardiology into patient-centred neurological care research.

MCR is moving away from its cardiovascular origins toward clinical research in dementia and Parkinson's care, suggesting future collaborations should target neurodegeneration, ageing, and patient-centred care design.

How they like to work

MCR exclusively participates as a consortium partner, never coordinating — they contribute specialized expertise rather than leading project design. With 40 unique partners across just 3 projects, they operate in large, multi-country consortia (averaging ~13 partners per project). This profile suggests a reliable specialist contributor that integrates well into large teams without requiring a leadership role.

Despite only 3 projects, MCR has built a broad network of 40 partners across 14 countries, indicating they join large pan-European health consortia. Their base in Milan positions them well within Italy's strong clinical research ecosystem.

What sets them apart

MCR occupies a rare niche as a private company that combines cardiovascular modelling experience with hands-on clinical research in neurodegenerative diseases — a combination few private research firms offer. Their dual background in computational trials (in-silico) and real-world care evaluation (dementia units, palliative care) means they can contribute to both the technical and patient-facing sides of health research projects. For consortium builders, they bring private-sector efficiency with academic-grade clinical research capabilities.

Highlights from their portfolio

• PD_Pal
  Largest funding (EUR 322,500) and represents their newest research direction into Parkinson's palliative care — a growing field with ageing demographics.
• RECAGE
  Most keyword-rich project addressing the ethically complex intersection of dementia behavioural management, non-pharmacologic therapies, and physical restraint ethics.